StreetInsider.com News Articles

Form 6-K Polyrizon Ltd. For: Jul 13

Mon, 13 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260713/26762392.html

Form 6-K Polyrizon Ltd. For: Jul 13

Mon, 13 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260713/26762392.html

Core AI Holdings names Arie Goor as CFO, effective July 1

Tue, 07 Jul 2026 08:20:14 -0400

Core AI Holdings, Inc. (NASDAQ: CHAI) announced the appointment of Arie Goor as Chief Financial Officer, effective July 1, 2026.

Goor, 43, brings more than 15 years of executive financial leadership experience in corporate finance, capital markets, and strategic transactions across the biotechnology, medical device, and technology sectors.

Before joining Core AI Holdings, Goor served as CFO of NYSE-listed Regentis Biomaterials (RGNT) from October 2022 to January 2026, and as CFO of Revium Rx from June 2023 to May 2026. He has led initial public offerings and capital markets transactions on exchanges including Nasdaq, the Australian Securities Exchange, the TSX Venture Exchange,

Core AI Holdings names Arie Goor as CFO, effective July 1

Tue, 07 Jul 2026 08:20:14 -0400

Core AI Holdings, Inc. (NASDAQ: CHAI) announced the appointment of Arie Goor as Chief Financial Officer, effective July 1, 2026.

Core AI Holdings names Arie Goor as CFO, effective July 1

Tue, 07 Jul 2026 08:20:14 -0400

Core AI Holdings, Inc. (NASDAQ: CHAI) announced the appointment of Arie Goor as Chief Financial Officer, effective July 1, 2026.

Form 6-K Polyrizon Ltd. For: Jul 02

Thu, 02 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260702/26727396.html

Form 6-K Polyrizon Ltd. For: Jul 02

Thu, 02 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260702/26727396.html

Polyrizon completes biocompatibility tests for NASARIX nasal spray

Thu, 02 Jul 2026 07:34:18 -0400

Polyrizon Ltd. (Nasdaq: PLRZ), an Israel-based development-stage biotech company, announced that its NASARIX™ Allergy Blocker nasal spray has completed a biocompatibility evaluation program, with all required biological safety tests meeting predetermined acceptance criteria.

The evaluation program was designed in accordance with ISO 10993 standards, FDA guidance, and European regulatory requirements. Testing covered cytotoxicity, sensitization, irritation and intracutaneous reactivity, material-mediated pyrogenicity, and acute systemic toxicity. Long-term systemic toxicity was assessed through a toxicological risk assessment conducted under ISO 10993-17.

The evaluation was based on the final NASARIX™ product configuration and incorporated assessments of formulation components, manufacturing processes, packaging materials, and intended patient exposure.

NASARIX™

Polyrizon completes biocompatibility tests for NASARIX nasal spray

Thu, 02 Jul 2026 07:34:18 -0400

NASARIX™

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Thu, 02 Jul 2026 07:32:00 -0400

Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced successful results from its biocompatibility evaluation program for its proprietary NASARIX^TM Allergy Blocker nasal spray, with all required biological safety tests meeting their predetermined acceptance criteria.

The comprehensive evaluation program was designed in accordance with internationally recognized standards for biological safety assessment of medical devices, including the ISO 10993 series, FDA guidance, and applicable European regulatory requirements. The program was developed to assess the safety and biocompatibility

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Thu, 02 Jul 2026 07:32:00 -0400

Form 6-K Polyrizon Ltd. For: Jun 29

Mon, 29 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260629/26706290.html

Form 6-K Polyrizon Ltd. For: Jun 29

Mon, 29 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260629/26706290.html

Polyrizon gets IRB approval for NASARIX allergy blocker trial

Mon, 29 Jun 2026 08:45:58 -0400

Polyrizon Ltd. (Nasdaq: PLRZ), an Israel-based development-stage biotech company, announced it received central institutional review board approval to begin its first human clinical trial for NASARIX, a nasal spray designed to block airborne allergens.

The approval was granted by the BRANY Institutional Review Board on June 18, 2026, and remains valid through June 17, 2027. It covers the study protocol, patient consent forms, and trial materials, confirming they satisfy applicable ethical and participant protection requirements.

The approved study, titled "Evaluation of the Efficacy, Safety, and Tolerability of NASARIX Allergy Blocker Compared to Saline Spray in Patients with Seasonal Allergic Rhinitis," will compare

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

Mon, 29 Jun 2026 08:44:00 -0400

Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, announced it has received central IRB approval to begin its first human clinical trial for NASARIX™, the Company’s innovative nasal spray designed to block airborne allergens.

This approval from BRANY Institutional Review Board (granted June 18, 2026) is a key regulatory milestone for the Company. It confirms that the study protocol, patient consent forms, and trial materials have been reviewed and approved by the central IRB and satisfy applicable

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

Mon, 29 Jun 2026 08:44:00 -0400

Form 6-K Polyrizon Ltd. For: Jun 17

Wed, 17 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260617/26659718.html

Form 6-K Polyrizon Ltd. For: Jun 17

Wed, 17 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260617/26659718.html

Polyrizon patent application for nasal drug delivery platform published in U.S.

Wed, 17 Jun 2026 08:16:18 -0400

Polyrizon Ltd. (Nasdaq: PLRZ), a development-stage biotech company based in Raanana, Israel, announced the publication of U.S. patent application No. US 2024/0358741 A1, titled "Mucoadhesive Polymers for Nasal Drug Delivery."

The application covers the company's Trap & Target mucoadhesive polymer technology platform, which is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa. According to the company, the technology aims to increase formulation retention, improve drug absorption, and enable delivery of active pharmaceutical ingredients through the nasal route.

The application describes biocompatible mucoadhesive compositions that combine sulfated polysaccharides with hydrophilic polymers, partially crosslinked with divalent ions. The resulting formulations

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Wed, 17 Jun 2026 08:15:00 -0400

Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the publication of U.S. patent application No. US 2024/0358741 A1, titled “Mucoadhesive Polymers for Nasal Drug Delivery”.

The patent application covers Polyrizon’s proprietary Trap & Target™ (T&T) mucoadhesive polymer technology platform for nasal drug delivery. The technology is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa, potentially increasing formulation retention, improving drug absorption, and enabling more efficient delivery of active pharmaceutical ingredients

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Wed, 17 Jun 2026 08:15:00 -0400

Form 6-K Polyrizon Ltd. For: Jun 15

Mon, 15 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260615/26647144.html

Form 6-K Polyrizon Ltd. For: Jun 15

Mon, 15 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260615/26647144.html

Polyrizon initiates human study for NASARIX allergy blocker

Mon, 15 Jun 2026 08:05:37 -0400

Polyrizon Ltd. (NASDAQ: PLRZ) announced it has executed agreements with a European university medical center and a clinical research organization to conduct a human study evaluating the nasal residence time of its NASARIX allergy blocker.

The study will measure how long the NASARIX formulation remains in the nasal cavity following administration, which the company states is intended to support estimation of the product's potential duration of protective barrier function.

The investigation is structured as a performance and characterization study rather than an interventional clinical trial focused on safety or efficacy. The study forms part of Polyrizon's verification and validation activities and is

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

Mon, 15 Jun 2026 08:05:00 -0400

New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier function

Raanana, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the execution of an agreement with a leading, internationally recognized European university medical center, alongside a contract with a specialized clinical research organization (CRO), to conduct a human study as part of its verification and validation (V&V) program for